With Empowered footing the bill for the deployment phase, costs are well under control. The financial stage for this company is set with the low OS and partners doing the heavy lifting.
Fintel has a public copy of the 10-Q from 2021-November-22.
Starting on page 5 the number of shares outstanding are listed by quarter starting in 2019, but I'm only going to list the last 4 quarter ending amounts.
10.5 million shares added in first 9 months of 2021. This does not account for the 7 million shares used to acquire Dry Eye Disease division that was finalized in October 2021.
September 30, 2021 135,885,104 shares
June 30, 2021 133,024,435 shares
March 31, 2021 127,528,507
December 31, 2020 125,327,579
FIRST 9 months of 2021 Loss from continuing operations: ($6,327,494 ) NET LOSS ($7,983,134 ) Revenue $ 55,651
I'm guessing the revenue was generated from the Recombinant protein created in-house by Alim Seit-Nebi, Chief Technology Officer.
News 
Market Data 
Discover 
